Factor XIII is a newly identified binding partner for platelet collagen receptor GPVI-dimer—An interaction that may modulate fibrin crosslinking

Masaaki Moroi PhD | Isuru Induruwa MBBS/BSc, PhD | Richard W. Farndale PhD | Stephanie M. Jung PhD

Abstract

Background: In the fibrin-forming process, thrombin cleaves fibrinogen to fibrin, which form fibrils and then fibers, producing a gel-like clot. Thrombin also activates coagulation factor XIII (FXIII), which crosslinks fibrin γ-chains and α-chains, stabilizing the clot. Many proteins bind to fibrin, including FXIII, an established regulation of clot structure, and platelet glycoprotein VI (GPVI), whose contribution to clot function is largely unknown. FXIII is present in plasma, but the abundant FXIII in platelet cytosol becomes exposed to the surface of strongly activated platelets.

Objectives: We determined if GPVI interacts with FXIII and how this might modulate clot formation.

Methods: We measured interactions between recombinant proteins of the GPVI extracellular domain: GPVI-dimer (GPVI-Fc2) or monomer (GPVIex) and FXIII proteins (nonactivated and thrombin-activated FXIII, FXIII subunits A and B) by ELISA. Binding to fibrin clots and fibrin γ-chain crosslinking were analyzed by immunoblotting.

Results: GPVI-dimer, but not GPVI-monomer, bound to FXIII. GPVI-dimer selectively bound to the FXIII A-subunit, but not to the B-subunit, an interaction that was decreased or abrogated by the GPVI-dimer–specific antibody mFab-F. The GPVI-dimer–FXIII interaction decreased the extent of γ-chain crosslinking, indicating a role in the regulation of clot formation.

Conclusions: This is the first report of the specific interaction between GPVI-dimer and the A-subunit of FXIII, as determined in an in vitro system with defined components. GPVI-dimer–FXIII binding was inhibitory toward FXIII-catalyzed crosslinking of fibrin γ-chains in fibrin clots. This raises the possibility that GPVI-dimer may negatively modulate fibrin crosslinking induced by FXIII, lessening clot stability.

Keywords: crosslinking, factor XIII, fibrin, fibrin clot, GPVI, GPVI-dimer, γ-chain, γ-dimer
INRTOCATION
Platelet collagen-receptor glycoprotein VI (GPVI) occurs as both monomers and constitutively present homodimers, the functional form. GPVI-dimers bind to exposed subendothelial collagen fibers in injured vessels, initiating a signaling cascade leading to platelet activation, aggregate formation, and thrombus formation. GPVI-dimer level is increased in activated platelets, and GPVI-dimer clustering in activated platelets brings associated signaling molecules in closer proximity, enhancing signaling. Activated platelets present a membrane surface complex that stimulates the coagulation reaction, increasing active thrombin production. These multiple processes culminate in formation of a platelet thrombus, which is stabilized by fibrin production due to thrombin generation on the surface of activated platelets.

GPVI has also been suggested to be a fibrinogen receptor, and fibrin fiber formation from fibrinogen enhances collagen-induced platelet activation. Whether GPVI can actually bind fibrinogen remains controversial. We recently demonstrated that GPVI-dimers, not monomers, bind to fibrin fibers in clots. Both collagen-initiated platelet activation and coagulation pathways are necessary to form a stable blood clot, comprising many platelets, fibrin fibers, and coagulation factors, ensuring effective hemostasis and wound repair. Clot retraction which contributes to wound closure depends on the integrin αIIbβ3-fibrin interaction, which allows the platelet cytoskeleton to draw fibrin fibers together. Coagulation factor XIII (FXIII) was also reported to be involved in clot retraction, although the mechanisms involved are yet not well defined.

Glycoprotein VI also binds to other proteins, including laminin, adiponectin, and extracellular matrix metalloproteinase inducer, so during the course of our studies on the GPVI-fibrin interaction, we explored whether it interacts with FXIII, part of the plasma milieu in which thrombus formation occurs.

Plasma FXIII is an inactive tetramer of two A- and two B-subunits (FXIII A1B2), until it is cleaved by thrombin in the presence of calcium, which removes the activation peptide from subunit A, freeing it from the complex, and converting it to the active form (FXIII Aa, where “a” designates an active form) that functions as a transglutaminase. Platelet cytosol also contains abundant FXIII as active FXIII A2γ, which is further activated by thrombin to FXIII Aa. Platelet FXIII was reported to be involved in clot retraction, platelet spreading and adhesion (as reviewed in Muszbek et al.), and platelet FXIII was shown to crosslink several proteins to the platelet cytoskeleton, suggesting that it may be involved in platelet morphological change. However, FXIII deficiency does not affect platelet aggregation, indicating that it does not contribute to this process. Although FXIII is not exposed on the surface of resting platelets, it is surface expressed upon strong platelet activation. FXIII Aa crosslinks fibrin γ-chains, forming γ-dimers (γ-γ), and further crosslinks γ- and α-chains, forming higher-molecular-weight products. Crosslinked fibrin clots would be more stable and more resistant to fibrinolysis.

Platelets have been shown to participate in numerous coagulation processes, including fibrin formation, and therefore in this study we asked whether fibrin-binding GPVI-dimer may interact with FXIII, found in both platelets and plasma. We demonstrate that GPVI-dimers specifically and directly interact with FXIII, and its inhibitory effect on γ-fibrin crosslinking suggests that this interaction may modulate fibrin clot integrity.

MATERIALS AND METHODS

2.1 Materials
Table 1 shows the FXIII proteins (and their abbreviations) used in this study and their affinity constants ($K_D$) for binding to GPVI-dimer. PK1 fibrinogen (FXIII-), plasminogen-, fibronectin-free; Enzyme Research Laboratories, UK); recombinant proteins of human GPVI-extracellular domain: GPVI-Fcγ(dimer) and GPVIex (monomer), developed by Moroi and Jung, were previously described. The following antibodies were used: rabbit monoclonal antibody against human FXIIIa (EPR1360) and rabbit polyclonal anti-fibrinogen γ-chain antibody (AB96532) (Abcam, Cambridge, England); 1G5 (mouse monoclonal anti-GPVI; Biocytex, Marseille, France); AlexaFluor-647–conjugated streptavidin (Jackson Immunoresearch Laboratories, West Grove, PA, USA); and IRDye 800CW anti-human antibody, IRDye 800CW anti-rabbit antibody, and IRDye 680RD anti-rabbit antibody (Li-Cor, Lincoln, NE, USA).

2.2 ELISA to measure GPVI-Fcγ binding to FXIII proteins
FXIII proteins, collagen (positive control), or bovine serum albumin (BSA; negative control) was incubated with ELISA plate wells (Nunc MaxiSorp, Thermo Fisher Scientific, Waltham, MA, USA) at 10 μg/mL (overnight, 4°C), and blocked with 0.5% BSA. The prepared wells were used for GPVI-Fcγ (GPVI-dimer) and GPVIex (GPVI-monomer) binding assays as previously described. Bound GPVI-Fcγ and GPVIex were detected by 1G5/IRDye 800CW anti-mouse antibody and quantified using an Odyssey CLx fluorescence imaging system (Li-Cor).
TABLE 1  Human FXIII proteins and their affinities to GPVI-dimer

| Material (abbreviations)                   | Details                                      | $K_D$ ($\mu$M) |
|-------------------------------------------|----------------------------------------------|----------------|
| Plasma FXIII$^a$ (FXIII$\alpha$$_2$$\beta_2$) | Tetrameric, not activated                     | 0.216 ± 0.067  |
| FXIII A-subunit$^b$ (rh-FXIIIA$\alpha_2$)  | Recombinant (rh)                             | 0.366 ± 0.047  |
| FXIII A-subunit (activated)$^b$ (rh-FXIIIA$\alpha_a$) | Thrombin-activated form of rh-FXIIIA$\alpha_2$ | 0.140 ± 0.011  |
| FXIII B-subunit$^b$ (rh-FXIII$\beta_2$)    | Recombinant (rh)                             | Too low to be determined |

Note: The FXIII proteins were obtained from the following suppliers: $^a$Fisher Scientific, Leicestershire, UK; and $^b$Zedira, Darmstadt, Germany. Binding affinities ($K_D$) were calculated from the binding curves shown in Figure 1B; data are expressed as values of the mean ± SEM (n = 8). The binding affinity of the fully activated form of the FXIII A-subunit is comparable to GPVI-dimer’s affinity to collagen type III (0.183 ± 0.026). Abbreviations: FVIII, factor VIII; GPVI, glycoprotein VI; SEM, standard error of the mean.

2.3 Immunoblotting analysis by clot assay

GPVI-Fc$\gamma_2$ and FXIII binding to fibrin fibers and its effects on fibrin crosslinking were analyzed using a fibrin clot assay.$^9$ Figure 3A shows a schematic of a typical clot assay experiment. Each reaction mixture containing PK1-fibrinogen, GPVI-Fc$\gamma_2$, 2 mM Ca$^{2+}$, and FXIII$\alpha_2$$\beta_2$ was clotted by adding thrombin (1 U/mL). Each clot was isolated, washed thoroughly, dissolved in 8 M urea/2% SDS/5 mM 2-mercaptoethanol and subjected to SDS-PAGE/western blotting. To detect GPVI-Fc and FXIII, respectively, the same blot was stained with IRDye 800CW anti-human antibody and rabbit anti-FXIII/IRDye 680RD anti-rabbit antibody; band fluorescence was quantified following fluorescence imaging (Odyssey, Li-Cor) and normalized to the respective protein band in the original uncotted sample and expressed as a percentage. On a separate blot of the same clot sample, the amounts of fibrin $\gamma$-chain and $\gamma$-dimer ($\gamma\gamma$) were detected by rabbit polyclonal anti-fibrinogen $\gamma$-chain antibody/IRDye 800CW anti-rabbit antibody and expressed as a percentage of the $\gamma$-chain band in the uncotted sample.

To determine if FXIII crosslinks GPVI-Fc$\gamma_2$ to other proteins, GPVI-Fc$\gamma_2$ (50 $\mu$g/mL), FXIII$\alpha_2$$\beta_2$ (0, 2, or 100 $\mu$g/mL), 2 mM Ca$^{2+}$, and thrombin (1 U/mL), in the presence or absence of PK1-fibrinogen, were reacted for 1 hour at 37°C. Some samples contained bovine transglutaminase (1 mM; Sigma-Aldrich, St. Louis, MO, USA), to incorporate biotin into substrates of FXIII. Immunoblotted membranes were stained by IRDye 800CW anti-human antibody (Li-Cor) for GPVI-Fc and AlexaFluor-647-conjugated streptavidin for biotin-incorporated bands and visualized by fluorescence imaging (Odyssey, Li-Cor).

3 RESULTS AND DISCUSSION

3.1 GPVI-Fc$\gamma_2$ specifically binds to FXIII

GPVI-Fc$\gamma_2$ binds with higher affinity to crosslinked fibrin than to noncrosslinked fibrin,$^9$ suggesting that FXIII may affect its binding or crosslinked fibrin would show a higher affinity to GPVI-Fc$\gamma_2$. An ELISA assay was used to determine whether GPVI-Fc$\gamma_2$ and FXIII proteins are capable of direct interaction, as shown in Figure 1A (relative levels of binding at fixed GPVI-Fc$\gamma_2$ concentration) and Figure 1B (concentration-dependency curves for calculation of $K_D$ (dissociation constant) values summarized in Table 1). rh-FXIIIA$\alpha_2$ (0.140 ± 0.011 $\mu$M) had the highest affinity, which was similar to the $K_D$ for collagen type-III (0.183 ± 0.026 $\mu$M). Although subunit B (rh-FXIII$\beta_2$) shows some binding to GPVI-Fc$\gamma_2$ at 50 $\mu$g/mL (Figure 1A, chartreuse bar), its concentration-dependency curve (Figure 1B, chartreuse squares) indicates that it scarcely binds to GPVI-Fc$\gamma_2$ having a nearly linear binding curve, reminiscent of a nonspecific interaction, precluding calculation of $K_D$. These data indicate that the activated form of subunit A binds most strongly to GPVI-Fc$\gamma_2$. In contrast, GPVI-monomer (GPVI$\gamma_2$) does not bind to any form of FXIII (Figure 1C) and binds only weakly to collagen-III, indicating that GPVI must be in its dimeric form to bind to FXIII.

3.2 FXIII binding to GPVI-Fc$\gamma_2$ abrogated by inhibitory GPVI-dimer-specific antibody

Figure 1D shows that although the binding of GPVI-Fc$\gamma_2$ to collagen is moderately inhibited by high concentration of the GPVI-dimer-specific antibody mFab-F (200 $\mu$g/mL), this concentration severely decreases or abrogates GPVI-Fc$\gamma_2$ binding to all the FXIII-related proteins. This suggests that FXIII may bind near the collagen-binding site of GPVI-Fc$\gamma_2$ since GPVI-Fc$\gamma_2$, not GPVI$\gamma_2$, binds specifically to collagen fibers$^2$ and its binding to FXIII is also dimer-specific (Figure 1C). Addition of ZED A108, FXIII-transglutaminase inhibitor (Zedira, Darmstadt, Germany), had no effect on GPVI-dimer binding to FXIII (data not shown), showing that the transglutaminase activity of FXIII is not involved in the binding interaction, suggesting that GPVI-dimer-bound FXIII may retain enzymatic activity for a small substrate like bovine transglutaminase.

Our data indicate that the active form of GPVI, GPVI-dimer, exclusively binds to FXIII A-subunit and complex FXIII$\alpha_2$$\beta_2$ while showing little interaction with subunit B. Notably, FXIII subunit B, not subunit A, was reported to bind to fibrinogen and stimulate activation of FXIII on fibrin.$^{21}$ This means that platelet FXIII$\alpha_2$ could bind to GPVI-dimers since it is exposed on the cell surface of...
strongly activated platelets. Mitchell et al. showed that platelet FXIII-induced fibrin crosslinking occurs when no plasma FXIII is present, suggesting that active FXIII is exposed on the platelet surface, performing its function to crosslink fibrin chains. FXIII of activated platelets localizes in sphingomyelin-rich rafts, and GPVI was also present in rafts on the platelet membrane. This raises the tantalizing possibility that GPVI dimer on the platelet membrane may serve as a receptor for platelet FXIII. Since the A-subunit is an active subunit, the interaction with GPVI might also influence the transglutaminase activity of FXIII from plasma or platelets, modulating the crosslinking of fibrin clots.

3.3 | GPVI is not a principal substrate of FXIII

It can be hypothesized that FXIII might crosslink GPVI to fibrin since GPVI binds more to crosslinked fibrin than to noncrosslinked fibrin. We tested this using reaction mixtures comprising GPVI-Fc2, FXIII A2B2, thrombin (1 U/mL), 2 mM Ca2+, and bismidopentylamine in the presence or absence of FXIII-free fibrinogen and determined if the transglutaminase activity of FXIII can transfer the biotinyl moiety from biotinamidopentylamine to GPVI dimer, which would indicate that GPVI dimer is a substrate of FXIII. Figure 2A shows a western blot simultaneously stained for GPVI-Fc2, thrombin activated FXIII (thrombin activated FXIII A2), FXIII A2B2, and collagen type III. The obtained K0.5s are described in Table 1. The P value (n = 4) comparing no mFab-F addition and addition of mFab-F (+fab) of each FXIII protein is shown above each set of bars. The addition of mFab-F (200 µg/mL) dramatically decreased or abrogated the binding of GPVI-Fc2 to all the FXIII. FVIII, factor VIII; GPVI, glycoprotein VI
some GPVI-crosslinking may occur at high FXIII concentrations. In the fibrin clot, biotin was incorporated to fibrin α-chain, γ-γ dimer, and higher-molecular-weight bands, but little GPVI-Fc (green) was associated with bands with molecular weight higher than GPVI-Fc, suggesting that GPVI-Fc would not be crosslinked to fibrin under our experimental conditions where FXIII is used at concentrations of 1–5 μg/mL. This figure indicates that crosslinking occurred predominantly in the fibrin γ- and α-chains.

### 3.4 GPVI-dimer–FXIII interaction in fibrin clots

We determined if FXIII might affect GPVI-dimer binding to fibrin fibers and vice versa using our clot binding assay, which determines fibrin-bound proteins by western blotting (Figure 3A: assay schematic and detailed in ref. 9). FXIII-free fibrinogen is converted to fibrin by thrombin under different concentrations of FXIII-A2B2 (0, 1, 5 μg/mL) and GPVI-Fc2 (0, 25, 50, 100 μg/mL). FXIII and GPVI-Fc2 bound to fibrin were detected by staining the western blots with anti-Fc and anti-FXIII A antibodies, respectively. Figure 3B (fibrin-bound GPVI-Fc vs GPVI-Fc2) shows that the dose-dependent increase in amount of GPVI-Fc bound to fibrin is not affected by the amount of FXIII added to the clotting mixture, and the amount of FXIII bound to fibrin does not change with the concentrations of GPVI-Fc2 in the clots (Figure 3C, fibrin-bound FXIII vs GPVI-Fc2). In this experiment, fibrinogen is converted to fibrin and FXIII-A2B2 is also activated to FXIII Aa by thrombin. The anti-FXIII Aa antibody employed is specific for FXIII Aa, so this result demonstrates the fibrin-specific binding of FXIII A2. Bymes et al.21 proposed a model where the FXIII B-subunit binds to fibrinogen, which stimulates FXIII A2 binding to fibrin D-domain after fibrin formation and FXIII activation. GPVI-dimer also binds to fibrinogen D-domain.20 This suggests that both proteins bind to the fibrin D-domain but as our results show, GPVI and FXIII independently interact with fibrin. However, since GPVI-Fc2 and FXIII can bind to each other, they could be in close proximity on the fibrin fiber.

The effect of GPVI-Fc2 on FXIII-catalyzed crosslinking was determined by the fibrin clot assay and quantitating bands on the
western blot stained by γ-chain–specific antibody. On the blots, γ- and γ-γ were identified by their molecular weight and the amounts calculated as percent of the amount of γ-chain in the original (non-clotted) sample. As shown in Figure 3D, adding FXIII at 1 μg/mL increases γ-dimer, and addition of GPVI-Fc2 decreases it (middle set of bars), but this effect was not evident at higher FXIII concentration (rightmost set of bars). Since the enzymatic activity of FXIII is not involved in the binding to GPVI-Fc2, the inhibitory activity...
of GPVI-Fc2 would be due to steric hinderance. In contrast, adding GPVI-Fc2 had no significant effect on the amount of γ-monomer (Figure 3E).

4 | CONCLUSION

Using an in vitro system of defined components, we demonstrated for the first time that GPVI-dimer specifically interacts with the FXIIIAa (activated A-subunit of FXIII), and FXIII and GPVI-dimer independently bind to fibrin at proximal sites in the fibrin D-domain. This suggests that the binding site for FXIII on GPVI-dimer is different from its fibrin-binding site and the binding site for GPVI-dimer on FXIIIA2 is different from its fibrin-binding site. We can hypothesize that the specific binding of GPVI-dimer to FXIIIAa demonstrated in our study may negatively modulate the crosslinking activity of FXIIIAa and thus affect clot stability. The occurrence of this interaction between GPVI-dimer and FXIII in the physiological context, in plasma and/or FXIII expressed on the activated platelet, and its function must be assessed in future work.

ACKNOWLEDGMENTS

This study was supported by a Project Grant from the British Heart Foundation (SP/13/7/30575 to SMJ and RWF). It is funded by a NIHR Academic Clinical Lectureship (RGB5316), was supported by a British Heart Foundation Cambridge Centre of Research Excellence fellowship (RE/13/6/30180) and an Addenbrookes Charitable Trust grant.

RELATIONSHIP DISCLOSURE

None of the authors have any conflicts of interests to report.

AUTHOR CONTRIBUTIONS

SMJ and MM designed and performed experiments, provided reagents, analyzed data, wrote the manuscript, and made the figures. II designed and performed experiments and read and made suggestions about the manuscript. RWF critically read the manuscript and made suggestions.

ORCID

Masaki Moroi https://orcid.org/0000-0003-4656-2319
Isuru Induruwa https://orcid.org/0000-0002-7020-8179
Richard W. Farndale https://orcid.org/0000-0001-6130-8808
Stephanie M. Jung https://orcid.org/0000-0002-7409-9715

TWITTER

Isuru Induruwa @iamthatiz

REFERENCES

1. Jung SM, Tsuji K, Moroi M. Glycoprotein (GP) VI dimer as a major collagen-binding site of native platelets: direct evidence obtained with dimeric GPVI-specific Fabs. J Thromb Haemost. 2009;7:1347-1355.
2. Jung SM, Moroi M, Soejima K, et al. Constitutive dimerization of Glycoprotein VI (GPVI) in resting platelets is essential for binding to collagen and activation in flowing blood. J Biol Chem. 2012;287:30000-30013.
3. Poultet NS, Pollitt AY, Owen DM, et al. Clustering of glycoprotein VI(GPVI) dimers upon adhesion to collagen as a mechanism to regulate GPVI signaling in platelets. J Thromb Haemost. 2017;15:549-564.
4. Watson SP, Herbert JM, Pollitt AY. GPVI and CLEC-2 in hemostasis and vascular integrity. J Thromb Haemost. 2010;8:1457-1467.
5. Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest. 2005;115:3355-3362.
6. Farndale RW, Slatter DA, Siljander PRM, Jarvis GE. Platelet receptor recognition and cross-talk in collagen-induced activation of platelets. J Thromb Haemost. 2007;5:220-229.
7. Mammadova-Bach E, Ollivier V, Loyau S, et al. Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. Blood. 2015;126:683-691.
8. Alshehri OM, Hughes CE, Montague S, et al. Fibrin activates GPVI in human and mouse platelets. Blood. 2015;126:1601-1608.
9. Moroi M, Induruwa I, Farndale RW, Jung SM. Dimers of the platelet collagen receptor glycoprotein VI bind specifically to fibrin fibers during clot formation, but not to intact fibrinogen. J Thromb Haemost. 2021;19:2056-2067.
10. Mangin PH, Onselaer M-B, Receveur N, et al. Immobilized fibrinogen activates human platelets through glycoprotein VI. Haematologica. 2018;103:898-907.
11. Haling JR, Monkley SJ, Critchley DR, Petrich BG. Talin-dependent integrin activation is required for fibrin clot retraction by platelets. Blood. 2011;117:1719-1722.
12. Mitchell JL, Lionikiene AS, Fraser SR, Whyte CS, Booth NA, Mitch NJ. Functional factor XIII-A is exposed on the stimulated platelet surface. Blood. 2014;124:3990.
13. Kasahara K, Kaneda M, Miki T, et al. Clot retraction is mediated by factor XIII-dependent fibrin-β1β3-myxosin axis in platelet sphingomyelin-rich membrane rafts. Blood. 2013;122:3340-3348.
14. Kasahara K, Souri M, Kaneda M, Mild T, Yamamoto N, Ichinose A. Impaired clot retraction in factor XIII A subunit-deficient mice. Blood. 2010;115:1277-1279.
15. Inoue O, Suzuki-Inoue K, McCarty OJ, et al. Laminin stimulates spreading of platelets through integrin α6/1-dependent activation of GPVI. Blood. 2006;107:1405-1412.
16. Ribas R, Hughes CE, Graham A, Watson SP, Naseem M. Globular adiponectin induces platelet activation through the collagen receptor GPVI-Fc receptor g chain complex. J Thromb Haemost. 2008;6:1012-1020.
17. Seizer P, Borst O, Langer HF, et al. EMMPRIN (CD147) is a novel receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN interaction. Thromb Haemost. 2009;101:682-686.
18. Muszbek L, Bereczky Z, Bagoly Z, Komaromi I, Katona E. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev. 2011;91:931-972.
19. Serrano K, Devine DV. Intracellular factor XIII crosslinks platelet cytoskeletal elements upon platelet activation. Thromb Haemost. 2002;88:315-320.
20. Induruwa I, Moroi M, Bonna A, et al. Platelet collagen receptor glycoprotein VI-dimer recognizes fibrinogen and fibrin through their D-domains, contributing to platelet adhesion and activation during thrombus formation. J Thromb Haemost. 2018;16:389-404.
21. Bymes JR, Wilsonn C, Boutelle AM, et al. The interaction between fibrinogen and zymogen FXIII-A2B2 is mediated by fibrinogen residues gamma 390–396 and the FXIII-B subunits. Blood. 2016;128:1969-1978.
22. Mitchell JL, Mitch NJ. Novel aspects of platelet factor XIII function. Thromb Res. 2016;14152:S17-S21.
23. Mitchell JL, Mutch NJ. Let’s cross-link: diverse functions of the promiscuous cellular transglutaminase factor XIII-A. J Thromb Haemost. 2019;17:19-30.

24. Ezumi Y, Kodama K, Uchiyama T, Takayama H. Constitutive and functional association of the platelet collagen receptor glycoprotein VI-Fc receptor γ-chain complex with membrane rafts. Blood. 2002;99:3250-3255.

25. Nikolajsen CL, Dyrlund TF, Poulsen ET, Enghild JJ, Scavenius C. Coagulation factor XIIa substrates in human plasma. Identification and incorporation into the clot. J Biol Chem. 2014;289:6526-6534.

How to cite this article: Moroi M, Induruwa I, Farndale RW, Jung SM. Factor XIII is a newly identified binding partner for platelet collagen receptor GPVI-dimer—An interaction that may modulate fibrin crosslinking. Res Pract Thromb Haemost. 2022;6:e12697. doi:10.1002/rth2.12697